Opinion|Videos|November 4, 2024
Perceptions on the Future of Bispecific Therapies for NHL
Panelists discuss their perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, highlighting key unmet needs and sharing clinical pearls for community oncologists.
Advertisement
Video content above is prompted by the following:
- What do you perceive the future to look like for patients being treated with bispecific antibodies for non-Hodgkin lymphoma?
- What remain the key unmet needs?
Do you have any clinical pearls for the community oncologist?
Advertisement
Related to this article
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Arvind N. Dasari, MD, MS, reviews a year in neuroendocrine tumors marked by expanding radioligand options, improved classification, and disappointing combination therapies.
Older age, kidney disease, and prior irradiation were linked to elevated myeloid neoplasm risk after lutetium Lu 177 dotatate in a real-world NET analysis.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Claire K. Mulvey, MD, explains how patient-reported outcomes and QOL assessments reveal NEN symptom burden and help guide treatment.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Liver transplant led to durable survival in unresectable NET liver metastases; tumor burden predicted outcomes, and recurrence was common but treatable.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Advertisement
Advertisement
Trending on Targeted Onc
1
NETs Year in Review: RLT Advances as Combo Strategies and ICIs Show Limited Benefit
2
Dr Chauhan on Oncolytic Virus SVV-001 Plus Ipi/Nivo in Neuroendocrine Cancers
3
Dr Dasari on Emerging PRRT Options and New Therapeutic Targets in NETs
4
Real-World Data Reveal Risk Factors for Myeloid Neoplasm After Lutetium Lu 177 Dotatate
5